A Study of the Treatment-Sparing Effects of AEROVANT™ AER 001 Inhalation Powder in Asthma Patients, AEROTRIAL
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
A multi-center, Phase IIb, double-blind, randomized, placebo controlled, parallel-group,
repeated-dose study in male and female patients with moderate to severe asthma in which
patients will be stabilized on AEROVANT then doses of inhaled corticosteroids and LABA will
be tapered. The hypothesis is that AEROVANT will improve asthma symptom control and decrease
the need for inhaled corticosteroids and LABA, thus improving exacerbation incidence compared
to placebo. Incidence of asthma exacerbation is the primary endpoint.